Want to see HK:2576 full AI Analyst Report?
Top Page
Zhejiang Taimei Medical Technology Co Ltd Class H
(2576)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$5.00
▲(19.05% Upside)
Action:Reiterated
Date:10/08/26
Overall score is held back primarily by ongoing losses and persistently negative operating/free cash flow despite signs of operational improvement and a low-debt balance sheet. Technical indicators lean slightly bearish (below key moving averages with negative MACD), and valuation is difficult to justify on earnings due to the negative P/E and no dividend yield provided.
Positive Factors
Strong 2025 revenue rebound
The sharp 2025 revenue rebound indicates materially stronger business activity and customer demand than in prior periods. If the higher revenue base can be maintained, it should improve operating leverage, support investment in the platform, and strengthen the company’s path toward sustainable profitability.
Negative Factors
Business remains loss-making
Negative EBIT and EBITDA show that the operating model has not yet converted improved revenue and margins into sustainable earnings. Until the company reaches operating profitability, growth may continue to require external funding and management must prove that recent improvements can persist across future reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong 2025 revenue rebound
The sharp 2025 revenue rebound indicates materially stronger business activity and customer demand than in prior periods. If the higher revenue base can be maintained, it should improve operating leverage, support investment in the platform, and strengthen the company’s path toward sustainable profitability.
Read all positive factors
Zhejiang Taimei Medical Technology Co Ltd Class H (2576) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.76B
Dividend YieldN/A
Average Volume (3M)484.45K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees687
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.12
Shares Outstanding200,592,530
10 Day Avg. Volume198,980
30 Day Avg. Volume484,453
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.79
Price to Sales (P/S)4.02
P/FCF Ratio-46.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhejiang Taimei Medical Technology Co Ltd Class H Business Overview & Revenue Model
Company Description
Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The c...
Zhejiang Taimei Medical Technology Co Ltd Class H Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 531.96M | 499.28M | 551.16M | 573.14M | 549.22M | 466.18M |
| Gross Profit | 235.10M | 211.91M | 224.94M | 179.00M | 185.40M | 163.59M |
| EBITDA | -61.75M | -28.60M | -176.73M | -302.97M | -364.38M | -440.39M |
| Net Income | -65.15M | -41.74M | -214.61M | -346.78M | -412.91M | -479.61M |
Balance Sheet | ||||||
| Total Assets | 1.50B | 1.56B | 1.58B | 1.44B | 1.83B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 1.19B | 1.20B | 1.07B | 1.41B | 1.40B |
| Total Debt | 85.39M | 61.16M | 34.76M | 28.64M | 81.47M | 77.44M |
| Total Liabilities | 348.40M | 365.62M | 348.62M | 402.56M | 441.97M | 393.75M |
| Stockholders Equity | 1.08B | 1.12B | 1.16B | 978.33M | 1.31B | 1.41B |
Cash Flow | ||||||
| Free Cash Flow | -26.87M | -43.15M | -207.30M | -360.64M | -357.44M | -249.94M |
| Operating Cash Flow | -23.75M | -39.38M | -201.62M | -351.16M | -329.22M | -217.53M |
| Investing Cash Flow | 284.09M | 328.99M | -283.68M | 237.69M | -5.88M | -379.35M |
| Financing Cash Flow | 49.11M | 24.90M | 281.04M | -39.28M | 285.59M | -40.08M |
Zhejiang Taimei Medical Technology Co Ltd Class H Technical Analysis
Negative
4.20
Price Trends
5.20
Negative
5.32
Negative
4.93
Negative
Market Momentum
-0.13
Negative
41.16
Neutral
45.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2576, the sentiment is Negative. The current price of 4.2 is below the 20-day moving average (MA) of 4.82, below the 50-day MA of 5.20, and below the 200-day MA of 4.93, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 41.16 is Neutral, neither overbought nor oversold. The STOCH value of 45.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2576.
Zhejiang Taimei Medical Technology Co Ltd Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$858.39M | 5.56 | 21.83% | 8.70% | 35.78% | 131.58% | |
58 Neutral | HK$1.55B | 82.56 | 21.60% | ― | 151.97% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | HK$2.76B | -34.06 | -5.91% | ― | ― | ― | |
46 Neutral | HK$134.98M | -6.15 | 20.88% | ― | -25.58% | -12.50% |
* General Sector Average
HK:2576
Zhejiang Taimei Medical Technology Co Ltd Class H
4.61
-0.28
-5.73%
HK:1450
Century Sage Scientific Holdings Ltd
0.58
-0.31
-34.66%
HK:8148
Aurum Pacific (China) Group Ltd.
3.39
2.61
339.61%
HK:8156
Sinopharm Tech Holdings Limited
0.16
-0.05
-25.24%
Zhejiang Taimei Medical Technology Co Ltd Class H Corporate Events
Zhejiang Taimei Posts Higher Revenue but Wider Interim Loss
Aug 26, 2026
Zhejiang Taimei Medical Technology reported revenue of RMB263.6 million for the six months ended June 30, 2026, an 8% increase year-on-year, with gross profit rising 17.5% and margin improving to 44.7%. Despite higher sales and other income, the G...
Zhejiang Taimei Schedules Board Meeting to Approve Interim Results and Mull Dividend
Aug 14, 2026
Zhejiang Taimei Medical Technology Co., Ltd. has scheduled a board meeting for August 26, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.